These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24488324)

  • 1. Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects.
    Liu D; Jiang J; Zhang L; Tan F; Wang Y; Zhang D; Hu P
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):721-7. PubMed ID: 24488324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
    Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
    Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
    Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Liu J; Wu L; Wu G; Hu X; Zhou H; Chen J; Zhu M; Xu W; Tan F; Ding L; Wang Y; Shentu J
    Oncologist; 2016 Nov; 21(11):1294-1295d. PubMed ID: 27789778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
    Ni J; Liu DY; Hu B; Li C; Jiang J; Wang HP; Zhang L
    Cancer; 2015 Sep; 121 Suppl 17():3146-56. PubMed ID: 26331821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
    Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
    Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.
    Ruan CJ; Liu DY; Jiang J; Hu P
    Eur J Clin Pharmacol; 2012 Dec; 68(12):1677-80. PubMed ID: 22585284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
    Wang HP; Zhang L; Wang YX; Tan FL; Xia Y; Ren GJ; Hu P; Jiang J; Wang MZ; Xiao Y
    Chin Med J (Engl); 2011 Jul; 124(13):1933. PubMed ID: 22088449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
    Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
    Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry.
    Liu D; Jiang J; Zhang L; Tan F; Wang Y; Hu P
    Rapid Commun Mass Spectrom; 2011 Aug; 25(15):2131-40. PubMed ID: 21732454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
    Gao Z; Chen W; Zhang X; Cai P; Fang X; Xu Q; Sun Y; Gu Y
    Biomed Pharmacother; 2013 Jun; 67(5):351-6. PubMed ID: 23602321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
    Zhao Q; Wang YN; Wang B
    Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.